Skip to Main Content

Updates Regarding 2025-2026 Respiratory Syncytial Virus (RSV) Ordering

Date: 08/20/25

Superior HealthPlan would like to inform providers about updates for the upcoming Respiratory Syncytial Virus (RSV) season. Please review the information below, including important effective dates for RSV vaccines.

Nirsevimab (Beyfortus™):

Effective August 1, 2025, nirsevimab (Beyfortus™) vaccine will be available in the Vaccine Allocation and Ordering System (VAOS) for Texas Vaccines for Children (TVFC) providers.   

Manufacturer​

NDC​

Brand​

Description​

Sanofi Pasteur

49281-0575-15

Beyfortus™ (50 mg)

5 Pack: 1 dose syringe

Sanofi Pasteur

49281-0574-15

Beyfortus™ (100 mg)

5 Pack: 1 dose syringe

Providers should administer inventory from the 2024–2025 season (October 1 – March 31) before requesting additional doses, as the vaccine from the previous season is still valid until expiry.

Provider maximum stock levels (MSL) and suggested quantities in VAOS should be used appropriately to determine the quantity of doses to request on an order. The Texas Department of State Health Services (DSHS) Central Office will review all orders with a quantity requested that is greater than the suggested quantity. Responsible Entities (REs) are the main approving authority for orders. Only orders in “Approved status” will be reviewed by the DSHS Central Office, to allows REs adequate time to conduct order reviews.

Prior to approving high quantity requests, the following will be reviewed:

  • Provider reporting compliance.
  • Existing nirsevimab inventory.
  • Provider population data such as TVFC patients less than one year old.
  • TVFC patients one to two years old.
  • Reported nirsevimab administrations.

Orders may be reduced or denied in some circumstances.

Any unused doses after the administration period must be stored until the following RSV season and used through expiry.  

Recommendations for Use of Beyfortus™ Vaccine:

  • DSHS recommends infants aged < 8 months born during or entering their first RSV season to receive the following:
    • One dose of 50 mg for infants who weigh <11.02 lbs
    • One dose of 100 mg for infants who weigh ≥ 11.02 lbs
  • Infants aged 8–19 months who are at increased risk of severe RSV disease and entering their second RSV season are recommended to receive the following:
    • Two doses of 100 mg of nirsevimab (Beyfortus™)

Adverse events must be reported to the MedWatch Online Voluntary Reporting Form. If Beyfortus™ is co-administered with vaccines, providers must report vaccine administration errors to the Vaccine Adverse Event Reporting System (VAERS).

 Refer to the following resources for more information on nirsevimab (Beyfortus™) for infants:

Abrysvo™

Effective August 1, 2025, RSVpreF (Abrysvo™) vaccine will be available in VAOS for TVFC providers.   

Manufacturer  

NDC  

Brand (if available)

Description   

Pfizer  

00069-2465-01

Abrysvo™ (0.5ml)  

one pack – single-dose vial 

 

Recommendations for Use of Abrysvo™ Vaccine

Abrysvo™ is recommended for active immunization of pregnant women during weeks 32 through 36 of pregnancy using seasonal administration (September 1 – January 31) to prevent Lower Respiratory Tract Infection (LRTI) caused by RSV in infants from birth through six months. One 0.5 mL dose should be administered intramuscularly (preferably deltoid region of the upper arm).  

Vaccine administration errors and/or adverse events must be reported to the VAERS. 

Any unused doses after the administration period must be stored until the following RSV season and used through expiry. 

Refer to the following resources for more information on the RSV vaccine (Abrysvo™):    

Reminder for RSV Vaccine Procedure Code 90683

Effective for dates of service on or after October 1, 2024, RSV vaccine procedure code 90683 is a benefit of Texas Medicaid members. Please reference Effective 10/01/24: RSV Vaccine Procedure Code 90683 Becomes a Benefit of Texas Medicaid for more information.  

For questions, please contact your designated Provider Representative. To access their contact information, visit the Find My Provider Representative webpage.